title: Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.
abstract: This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of 'inhalation by design'. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.
authors.affiliation: Sandwich Chemistry, World Wide Medicinal Chemistry, Pfizer, Ramsgate Road, Sandwich CT13 9NJ, UK. lyn.jones@pfizer.com
authors.forename: Lyn H
authors.initials: LH
authors.lastname: Jones
authors.forename: Helen
authors.initials: H
authors.lastname: Baldock
authors.forename: Mark E
authors.initials: ME
authors.lastname: Bunnage
authors.forename: Jane
authors.initials: J
authors.lastname: Burrows
authors.forename: Nick
authors.initials: N
authors.lastname: Clarke
authors.forename: Michele
authors.initials: M
authors.lastname: Coghlan
authors.forename: David
authors.initials: D
authors.lastname: Entwistle
authors.forename: David
authors.initials: D
authors.lastname: Fairman
authors.forename: Neil
authors.initials: N
authors.lastname: Feeder
authors.forename: Craig
authors.initials: C
authors.lastname: Fulton
authors.forename: Laura
authors.initials: L
authors.lastname: Hilton
authors.forename: Kim
authors.initials: K
authors.lastname: James
authors.forename: Rhys M
authors.initials: RM
authors.lastname: Jones
authors.forename: Amy S
authors.initials: AS
authors.lastname: Kenyon
authors.forename: Stuart
authors.initials: S
authors.lastname: Marshall
authors.forename: Sandra D
authors.initials: SD
authors.lastname: Newman
authors.forename: Rachel
authors.initials: R
authors.lastname: Osborne
authors.forename: Sheena
authors.initials: S
authors.lastname: Patel
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Selby
authors.forename: Emilio F
authors.initials: EF
authors.lastname: Stuart
authors.forename: Michael A
authors.initials: MA
authors.lastname: Trevethick
authors.forename: Karen N
authors.initials: KN
authors.lastname: Wright
authors.forename: David A
authors.initials: DA
authors.lastname: Price
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage; D000818:Animals; D001559:Benzhydryl Compounds / Q000008:administration & dosage; D003408:Cresols / Q000008:administration & dosage; D015195:Drug Design; D004359:Drug Therapy, Combination; D006168:Guinea Pigs; D015394:Molecular Structure; D018727:Muscarinic Antagonists / Q000008:administration & dosage; D010665:Phenylpropanolamine / Q000008:administration & dosage; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D000068737:Tolterodine Tartrate
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate